Ryvu Therapeutics links up with Polpharma on APIs for RVU120 trials

6 July 2023

Ryvu Therapeutics (WSE: RVU), Poland’s largest biotech firm, said today it has signed two agreements with Zakłady Farmaceutyczne Polpharma relating to its lead candidate RVU120 active pharmaceutical ingredient (API) production for Phase II clinical studies in hematology: RIVER-52 and RIVER-81.

The agreements are essential elements of the implementation of Ryvu's Development Plans for 2022-2024.

Ryvu notes that the subject of the RIVER-52 study-related agreement is the execution of the API manufacturing campaign for RVU120 in the registration current Good Manufacturing Practice (cGMP) standard – a key element in preparing for the potential fast-to-market strategy implementation for the Phase II study of RVU120 as monotherapy in the treatment of patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK